Yaşlı Popülasyonda Üro-Psikiyatrik Polifarmasi: İlaç Etkileşimleri, Antikolinerjik Yük ve Güvenli Reçeteleme
Synopsis
Yaşlı bireylerde ürolojik ve psikiyatrik hastalıkların sık birlikteliği, çoklu ilaç kullanımını ve buna bağlı güvenlik sorunlarını artırmaktadır. Yaşa bağlı farmakokinetik ve farmakodinamik değişiklikler; antikolinerjik yük, sedasyon, ortostatik hipotansiyon, hiponatremi, renal fonksiyon bozukluğu, üriner retansiyon, inkontinans, düşme ve deliryum gibi advers sonuçlara duyarlılığı belirginleştirir. Bu bölümde yaşlı popülasyonda sık kullanılan ürolojik ve psikiyatrik ilaçların karşılıklı etkileri, klinik açıdan önemli ilaç etkileşimleri ve reçete kaskadı riski ele alınmaktadır. Ayrıca böbrek fonksiyonunun ilaç seçimine etkisi, yüksek riskli kombinasyonların tanınması, düzenli ilaç gözden geçirme ve deprescribing yaklaşımları tartışılmaktadır. Geriatrik üro-psikiyatrik hastalarda güvenli reçeteleme; yalnızca hedef semptoma yönelik ilaç seçimini değil, bilişsel durumun, kırılganlığın, düşme riskinin, renal fonksiyonların ve toplam ilaç yükünün birlikte değerlendirilmesini gerektirir.
References
Nishii H. A review of aging and the lower urinary tract: the future of urology. International Neurourology Journal. 2021;25(4):273.
Cheng S, Lin D, Hu T, Cao L, Liao H, Mou X, et al. Association of urinary incontinence and depression or anxiety: a meta-analysis. Journal of International Medical Research. 2020;48(6):0300060520931348.
Lee DY, Kam SC. Should psychiatric symptoms be evaluated in elderly males with lower urinary tract symptoms? International Neurourology Journal. 2023;27(2):155.
Saberian M, Amirabadizadeh A, Saatchi M, Delbari A. Lower urinary tract symptoms (LUTS) and sleep quality: the mediating role of anxiety and depression in middle-aged and older adults from the ardakan cohort study on aging (ACSA). BMC urology. 2025;25(1):157.
Zazzara MB, Palmer K, Vetrano DL, Carfì A, Onder G. Adverse drug reactions in older adults: a narrative review of the literature. European geriatric medicine. 2021;12(3):463-73.
Charles CV. 2023 AGS beers criteria® for potentially inappropriate medication use in older people: a summary of the updates. The Senior Care Pharmacist. 2023;38(9):352-4.
O’Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart J-B, Onder G, et al. STOPP/ START criteria for potentially inappropriate prescribing in older people: version 3. European geriatric medicine. 2023;14(4):625-32.
Doherty AS, Shahid F, Moriarty F, Boland F, Clyne B, Dreischulte T, et al. Prescribing cascades in communitydwelling adults: a systematic review. Pharmacology Research & Perspectives. 2022;10(5):e01008.
Bryła A, Woroń J, Miedziaszczyk M, Lorkowska-Zawicka B, Bujak-Giżycka B, Orzechowski D, et al. Prescribing cascade as a therapeutic error: a danger for geriatric patients with multimorbidity. Geriatrics. 2026;11(2):37.
Aggarwal P, Woolford SJ, Patel HP. Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice. Geriatrics. 2020;5(4):85.
Navickas R, Petric V-K, Feigl AB, Seychell M. Multimorbidity: What do we know? What should we do? Journal of comorbidity. 2016;6(1):4-11.
Rochon PA, Gurwitz JH. The prescribing cascade revisited. The Lancet. 2017;389(10081):1778- 80.
Panel AGSBCUE. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023;71(7):2052-81.
Dobrek L. Lower urinary tract disorders as adverse drug reactions—a literature review. Pharmaceuticals. 2023;16(7):1031.
Orsel K, Taipale H, Raatikainen S, Lampela P, Tolppanen A-M, Koponen M, et al. Antipsychotic use and the risk of initiating medication for benign prostate hyperplasia in persons with alzheimer disease: a matched cohort study. Journal of Clinical Psychopharmacology. 2018;38(5):494-7.
Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. International journal of clinical practice. 2010;64(9):1279-86.
Vaughan CP, Brown CJ, Goode PS, Burgio KL, Allman RM, Johnson I, Theodore M. The association of nocturia with incident falls in an elderly communitydwelling cohort. International journal of clinical practice. 2010;64(5):577-83.
Mangoni AA, Jackson SH. Agerelated changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. British journal of clinical pharmacology. 2004;57(1):6-14.
Drenthvan Maanen AC, Wilting I, Jansen PA. Prescribing medicines to older people—How to consider the impact of ageing on human organ and body functions. British journal of clinical pharmacology. 2020;86(10):1921-30.
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug metabolism reviews. 2009;41(2):67-76.
Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clinical journal of the American Society of Nephrology. 2010;5(2):314-27.
Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. The Journal of urology. 2024;212(1):11-20.
Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourology and Urodynamics. 2022;41(8):1928-33.
Coupland CA, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA internal medicine. 2019;179(8):1084-93.
Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. European urology. 2019;75(6):988-1000.
Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5α-reductase inhibitors. JAMA internal medicine. 2017;177(5):683-91.
Przydacz M, Chlosta M, Dudek P, Cudnoch-Jedrzejewska A, Zgliczynski W, Dobruch J, et al. Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines. Central European journal of urology. 2020;73(4):498.
Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and metaanalysis. Neurourology and Urodynamics: Official Journal of the International Continence Society. 2004;23(4):302-5.
Verhamme KM, Sturkenboom MC, Stricker BHC, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug safety. 2008;31(5):373-88.
Uekusa S, Mogi K, Ota Y, Hanai Y, Kitagawa K, Yoshio T, et al. A pharmacovigilance study on psychotropic agent-induced urinary retention using the Japanese adverse drug event report database. Drugs-Real World Outcomes. 2024;11(4):691-700.
Trinchieri M, Perletti G, Magri V, Stamatiou K, Montanari E, Trinchieri A. Urinary side effects of psychotropic drugs: a systematic review and metanalysis. Neurourology and Urodynamics. 2021;40(6):1333-48.
Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry: John Wiley & Sons; 2025.
Panel AGSBCUE, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674-94.
Srifuengfung M, Pennington BRT, Lenze EJ. Optimizing treatment for older adults with depression. Therapeutic advances in psychopharmacology. 2023;13:20451253231212327.
Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. The Journal of clinical psychiatry. 1987;48(6):244-5.
Saddichha S, Kumar M. Antipsychotic-induced urinary dysfunction: anticholinergic effect or otherwise? BMJ Case Rep. 2009;2009.
Tanzer T, Warren N, McMahon L, Barras M, Kisely S, Brooks E, et al. Treatment strategies for clozapine-induced nocturnal enuresis and urinary incontinence: a systematic review. CNS spectrums. 2023;28(2):133-44.
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and clinical risk management. 2017:757-77.
Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet. 2013;382(9896):951-62.
Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PloS one. 2017;12(4):e0174730.
Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. International journal of bipolar disorders. 2016;4(1):27.
Filippatos TD, Makri A, Elisaf MS, Liamis G. Hyponatremia in the elderly: challenges and solutions. Clinical interventions in aging. 2017:1957-65.
Pinkhasov A, Xiong G, Bourgeois JA, Heinrich TW, Huang H, Coriolan S, et al. Management of SIADH-related hyponatremia due to psychotropic medications–An expert consensus from the Association of Medicine and Psychiatry. Journal of psychosomatic research. 2021;151:110654.
Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation. 2012;27(10):3736-45.
Dalal PK, Kar SK, Agarwal SK. Management of psychiatric disorders in patients with chronic kidney diseases. Indian Journal of Psychiatry. 2022;64(Suppl 2):S394-S401.